A Phase 2a, Multi Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Effect of 12 Weeks Treatment With Oral PXS-4728A on Microglia Activation, as Measured by Positron Emission Tomography, in Participants With Isolated Rapid Eye Movement Sleep Behavior Disorder
Latest Information Update: 16 Apr 2025
At a glance
- Drugs BI 1467335 (Primary)
- Indications REM-sleep-behavior-disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Syntara Limited
Most Recent Events
- 11 Apr 2025 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
- 11 Apr 2025 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited